proteins.
Alterations of the p53 tumour suppressor gene are the most common genetic abnormalities found in human cancer.' p53 mutations associated with overexpression of the gene have been described in a wide variety of human malignant tumours.28 p53 gene mutations generally lead to stabilisation of the protein which can then be detected by immunohistochemistry. Stabilisation may, however, also be achieved through binding to other cellular or viral proteins.'-9 Indeed, p53 inactivation independent of mutation has been reported in relation to associations with viral oncoproteins such as the SV40 large T antigen, HPV E6 in cervical carcinomas,'01' EBNA-5 protein of EBV,'2 or cellular proteins such as murine double-minute 2 (MDM-2) oncoprotein in some sarcomas. '3 The MDM-2 oncoprotein was identified in the spontaneously transformed Balb/c 3T3 cell line'4 and when amplified or overexpressed has been shown to increase the tumorigenic potential of cells.'5 The human MDM-2 gene was recently cloned and located on chromosome 12q13-14.'3 It has been found to be deregulated in human sarcomas, gliomas, breast carcinomas, and leukaemias.'316-19 The mechanism of this deregulation in sarcomas has been shown to be gene amplification, 13 while in leukaemias significantly high levels of MDM-2 mRNA expression were detected in the absence of MDM-2 gene amplification. '9 It has been suggested that other mechanisms such as alterations of cis or trans acting factors that regulate the MDM-2 expression may account for the MDM-2 overexpression in such leukaemias.'9 The MDM-2 gene encodes for a nuclear protein which contains two potential DNA metal binding motifs (zinc fingers), and a acid trans activator domain, suggesting that it may be a DNA binding protein. 15 MDM-2 protein can bind both wild and mutant p53,202' and MDM-2 overexpression can inhibit p53 transcriptional activity,22 by concealing the p53 acidic activation domain from the cellular transcription machinery.23 This may be one of the mechanisms of the transforming potential of the MDM-2 gene which could lead to malignant transformation.
In this study we have used immunohistochemistry to investigate the expression of MDM-2 protein in comparison to that of p53 protein in a series of 59 nasopharyngeal carcinomas. In a previous study,24 we found that p53 protein expression was more often detected in undifferentiated nasopharyngeal carcinoma, most of which were reported to display germ line configuration of p53 gene.2526 Thus we addressed the question of whether there is immunohistochemical evidence that MDM-2 protein is one of the factors responsible for the 23 30 it is possible that MDM-2 expression may be involved in the pathogenesis of some undifferentiated nasopharyngeal carcinomas by deregulating the p53 dependent growth suppressive pathway. The expression of MDM-2 protein in a substantial proportion of undifferentiated carcinomas but not in normal nasopharyngeal epithelium could be a result of MDM-2 amplification, RNA overexpression, or post-translational stabilisation in these tumours. In this respect, it is interesting to note that besides DNA amplification or stabilisation of the protein because ofbinding to p53, enhanced translation was recently reported as a mechanism of MDM-2 protein accumulation in human tumours. 32 (2) p53 protein expression without MDM-2 protein expression occurred in six cases (four undifferentiated nasopharyngeal carcinoma, one non-keratinising nasopharyngeal carcinoma, and one keratinising nasopharyngeal carcinoma). This pattern suggests deregulation of the self regulating feedback loop which is formed by the interaction between MDM-2 and p53 proteins.33 With regard to the cases of undifferentiated nasopharyngeal carcinoma, it is possible that other cellular or viral proteins may account for the stabilisation of the p53 protein, as suggested previously.34 Concerning non-keratinising and keratinising nasopharyngeal carcinomas, it is not known whether p53 mutations occur. If they do, it is possible that these mutations are unable to activate the MDM-2 gene. Alternatively, MDM-2 gene deregulation might have occurred in these cases in the absence of p53 gene mutations. It is of interest that MDM-2 protein expression was not found in the absence of p53 protein expression in nasopharyngeal carcinoma. This is in agreement with the finding that the absence of p53 protein will not allow MDM-2 transactivation,with the result that there is no expression of MDM-2.212229
In summary, our study shows that different patterns of concordant or discordant p53/ MDM-2 protein expression occur in nasopharyngeal carcinoma, thus suggesting that derangement of the feedback loop that regulates the expression of p53 and MDM-2 may play a role in the pathogenesis of a proportion of cases of nasopharyngeal carcinoma. Further studies at DNA and RNA level are required to clarify the molecular mechanisms which underlie the expression of MDM-2 protein in nasopharyngeal carcinoma. 
